4.7 Review

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19

Journal

VACCINES
Volume 10, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/vaccines10060951

Keywords

COVID-19; SARS-CoV-2; baricitinib; antiviral; anti-cytokine; immune modulator

Funding

  1. Future Health and Research Infrastructure fund of the Government of Western Australia

Ask authors/readers for more resources

This article discusses the impact of the Swiss variant of COVID-19 on mild patients in 2020 and the recommended use of a new anti-inflammatory drug. The article also compares the efficacy of this drug with other immune modulators and emphasizes the role of artificial intelligence in identifying new drug candidates.
During the current pandemic, the vast majority of COVID-19 patients experienced mild symptoms, but some had a potentially fatal aberrant hyperinflammatory immune reaction characterized by high levels of IL-6 and other cytokines. Modulation of this immune reaction has proven to be the only method of reducing mortality in severe and critical COVID-19. The anti-inflammatory drug baricitinib (Olumiant) has recently been strongly recommended by the WHO for use in COVID-19 patients because it reduces the risk of progressive disease and death. It is a Janus Kinase (JAK) 1/2 inhibitor approved for rheumatoid arthritis which was suggested in early 2020 as a treatment for COVID-19. In this review the AI-assisted identification of baricitinib, its antiviral and anti-inflammatory properties, and efficacy in clinical trials are discussed and compared with those of other immune modulators including glucocorticoids, IL-6 and IL-1 receptor blockers and other JAK inhibitors. Baricitinib inhibits both virus infection and cytokine signalling and is not only important for COVID-19 management but is non-immunological, and so should remain effective if new SARS-CoV-2 variants escape immune control. The repurposing of baricitinib is an example of how advanced artificial intelligence (AI) can quickly identify new drug candidates that have clinical benefit in previously unsuspected therapeutic areas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available